Patent Win For Sofosbuvir In India But "Tortured" Ruling Faces Appeal
India has approved a Gilead Sciences Inc. patent that claims the active metabolites of sofosbuvir amid allegations by opponents of "external pressures" on the patent office and that the decision "weakens" Section 3(d) of India's patent regulation.
You may also be interested in...
A recent Delhi High Court order that set aside the rejection of one of Gilead's key patent applications for its hepatitis C treatment, Sovaldi (sofosbuvir), in India has made some seemingly embarrassing observations on how the patent office may have been potentially ''influenced'' by material placed on record by pre-grant opposition applicants.
Sovaldi (sofosbuvir) licensee Cipla intends to keep a ''very keen eye'' on the product's affordability and hopes, going forward, to pare prices below Gilead Sciences' reported $900 offer in Egypt for a course of treatment with the product.
India's Supreme Court has dismissed with costs Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law (scripintelligence.com, 1 April 2013).